Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations.

[1]  D. Bell,et al.  Origins and molecular pathology of ovarian cancer , 2005, Modern Pathology.

[2]  A. Godwin,et al.  Tumor Necrosis Factor-α-Induced Matrix Proteolytic Enzyme Production and Basement Membrane Remodeling by Human Ovarian Surface Epithelial Cells , 2004, Cancer Research.

[3]  F. Penault-Llorca,et al.  Prophylactic oophorectomy , 2003, Cancer.

[4]  Elizabeth R. Smith,et al.  Etiology of epithelial ovarian cancer: a cellular mechanism for the role of gonadotropins. , 2003, Gynecologic oncology.

[5]  Rochelle L. Garcia,et al.  Pathologic findings in prophylactic oophorectomy specimens in high-risk women. , 2002, Gynecologic oncology.

[6]  D. Haber.  Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. , 2002, The New England journal of medicine.

[7]  J. Pfeilschifter,et al.  Changes in proinflammatory cytokine activity after menopause. , 2002, Endocrine reviews.

[8]  S. Ochsner,et al.  Ovulation: new dimensions and new regulators of the inflammatory-like response. , 2002, Annual review of physiology.

[9]  B. Rosen,et al.  Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status , 2001, The American journal of surgical pathology.

[10]  R. Kryscio,et al.  Relating ovarian size to age, menopausal status, and use of hormones. , 2001, Gynecologic oncology.

[11]  C. Finn.  Reproductive ageing and the menopause. , 2001, The International journal of developmental biology.

[12]  H. Lynch,et al.  Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. , 2000, Gynecologic oncology.

[13]  K. Offit,et al.  Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes , 2000, Cancer.

[14]  J. Niloff,et al.  Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Kelsey,et al.  Menopause : biology and pathobiology , 2000 .

[16]  A. Tsafriri,et al.  Molecular aspects of mammalian ovulation. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[17]  J Gil,et al.  Ovarian dysplasia in prophylactic oophorectomy specimens , 1999, Cancer.

[18]  R. Ness,et al.  Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.

[19]  D Lowe,et al.  Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. , 1999, Journal of the National Cancer Institute.

[20]  B. Werness,et al.  Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. , 1999, Human pathology.

[21]  S. Nilsson,et al.  Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence , 1998, Clinical endocrinology.

[22]  J. Boyd,et al.  Hereditary ovarian cancer: molecular genetics and clinical implications. , 1997, Gynecologic oncology.

[23]  A. Godwin,et al.  Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer , 1996, International journal of cancer.

[24]  A. Godwin,et al.  Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. , 1996, Journal of the National Cancer Institute.

[25]  M. Morgan,et al.  Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.

[26]  J. Rygaard,et al.  Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype. , 1995, Biology of reproduction.

[27]  G. Tortolero-Luna,et al.  The epidemiology of ovarian cancer , 1995, Journal of cellular biochemistry. Supplement.

[28]  Santa V. Nicasia,et al.  The aging ovary. , 1987, The Medical clinics of North America.

[29]  A. Whittemore,et al.  Gonadotrophins and ovarian cancer risk. , 1985, Journal of the National Cancer Institute.

[30]  D. Cramer,et al.  Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. , 1983, Journal of the National Cancer Institute.

[31]  J. C. Eldridge,et al.  Maturation of the negative feedback control of gonadotropin secretion in the female rat. , 1974, Endocrinology.

[32]  W. Beamer,et al.  Plasma gonadotropin levels during early stages of ovarian tumorigenesis in mice of the W x -W u genotype. , 1973, Cancer research.

[33]  E. Murphy.  Hyperplastic and early neoplastic changes in the ovaries of mice after genic deletion of germ cells. , 1972, Journal of the National Cancer Institute.

[34]  M F Fathalla,et al.  Incessant ovulation--a factor in ovarian neoplasia? , 1971, Lancet.